Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder

Psychiatry Res. 2013 Aug 15;208(3):285-7. doi: 10.1016/j.psychres.2013.04.021. Epub 2013 May 24.

Abstract

Responses to venlafaxine treatment in major depressive disorder were stratified by COMT genotypes (Val158Met, rs4680) in a randomized, double-blind, placebo-controlled clinical trial. Improvements in depression scores among subjects with Val/Val genotypes were larger than those in Met/Met genotypes, suggesting that venlafaxine may alter noradrenergic flux differentially according to COMT activity.

Keywords: COMT; Major depressive disorder; Venlafaxine.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Analysis of Variance
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Catechol O-Methyltransferase / genetics*
  • Cyclohexanols / therapeutic use*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / genetics*
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Genotype
  • Humans
  • Male
  • Methionine / genetics
  • Middle Aged
  • Pharmacogenetics*
  • Polymorphism, Genetic / genetics
  • Psychiatric Status Rating Scales
  • Time Factors
  • Valine / genetics
  • Venlafaxine Hydrochloride
  • Young Adult

Substances

  • Antidepressive Agents, Second-Generation
  • Cyclohexanols
  • Venlafaxine Hydrochloride
  • Methionine
  • Catechol O-Methyltransferase
  • Valine